JAK Signaling in Depression
NCT07003997
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study will test the hypothesis that Janus kinase (JAK) signaling is involved in major depression (MD) with high inflammation by determining whether its inhibition with baricitinib can improve functional connectivity in reward and motor circuits in association with improved motivation and motor function in MD patients enriched for high C-reactive protein (CRP) and anhedonia.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Major Depressive Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 25 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Emory University
- Last updated on ClinicalTrials.gov
- September 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 1
- Emory University · Atlanta, GA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.